Skip to main content
Immunofluorescence staining of MAIT cells (green) next to mononuclear phagocytes (red) in kidney sections of mice with experimental glomerulonephritis. Cell nuclei in blue. Image: Nature Communications, DOI: 10.1038/s41467-023-43269-0

News categories: Publication

Vitamin B2 Derivatives Can Alleviate Chronic Kidney Inflammation

Researchers from the University Medical Center Hamburg-Eppendorf and the University Hospital Bonn have demonstrated that certain derivatives of vitamin B2 can alleviate chronic kidney inflammation in mice. Their findings have been published in the journal “Nature Communications.”

The term glomerulonephritis denotes several types of chronic kidney inflammation that can lead to the loss of renal function. Most of these conditions are due to autoaggressive immune responses that damage the kidney tissue. Although glomerulonephritis can be treated with immunosuppressive drugs such as corticosteroids, sometimes there is no way of stopping the self-destructive immune response. This may lead to a complete loss of renal function, necessitating continuous dialysis or a kidney transplant.

Researchers led by Professor Jan-Eric Turner from the Center for Internal Medicine at the University Medical Center Hamburg-Eppendorf and by Professor Christian Kurts from the Institute of Molecular Medicine and Experimental Immunology at the University Hospital Bonn, who is a member of the ImmunoSensation2 Cluster of Excellence and the Life & Health Transdisciplinary Research Area at the University of Bonn, have now found that certain vitamin metabolites can support the treatment of these conditions.

The researchers were the first to observe so called mucosal-associated invariant T cells (MAIT cells) ins both healthy and inflamed human kidneys. These rare immune cells are normally found in mucosal tissue such as in the intestine or lungs, where they perform sentinel functions against infections. “They are activated by metabolites of vitamins B2 and B9, which many infectious bacteria produce, and trigger defense responses as a result,” Professor Kurts says.

MAIT cells protecting the kidney

“In kidneys of glomerulonephritis patients and of mice with models of such diseases, these rare immune cells were activated by the resident kidneys immune cells —known as mononuclear phagocytes— that produce molecules that attracted the MAIT cells,” Professor Turner explains. Mice that lacked MAIT cells or in which mononuclear phagocytes could not attract MAIT cells experienced a more severe progression of their glomerulonephritis. Conversely, some of the mice that possessed more MAIT cells were protected.

These findings suggested that MAIT cells play a protective role in the kidney. In a therapeutic trial, the researchers treated mice suffering from glomerulonephritis with an artificial vitamin B2 metabolite that matched their natural ligand, and this alleviated the disease progression.

“The protective effect was not strong enough to prevent the experimental glomerulonephritis entirely,” Professor Kurts concedes. However, the researchers believe that it could be used to supplement existing therapies and make them more effective or to reduce the dose of glucocorticoids required in treatment. “More research and clinical trials will be needed before this becomes a viable option in therapy,” Professor Turner points out.

Institutions involved and funding secured:

The University Medical Center Hamburg-Eppendorf, the University Hospital Bonn and the University of Bonn were joined by Institut Curie in Paris, the University of Melbourne, EUROIMMUN in Lübeck and the Paul-Ehrlich-Institut in Langen for the study. It was supported by the Collaborative Research Center CRC1192 “Immune-Mediated Glomerular Diseases” of the German Research Foundation (DFG) in Hamburg and by the ImmunoSensation2 Cluster of Excellence at the University of Bonn.

Publication: Ann-Christin Gnirck, Marie-Sophie Philipp, Alex Waterhölter, Malte Wunderlich, Nikhat Shaikh, Virginia Adamiak, Lena Henneken, Tobias Kautz, Tingting Xiong, Daniela Klaus, Pascal Tomczyk, Mohamad M. Al-Bahra, Dirk Menche, Mark Walkenhorst, Olivier Lantz, Anne Willing, Manuel A. Friese, Tobias B. Huber, Christian F. Krebs, Ulf Panzer, Christian Kurts and Jan-Eric Turner: “Mucosal-associated invariant T cells contribute to suppression of inflammatory myeloid cells in immune-mediated kidney disease,” in “Nature Communications,” Internet: https://www.nature.com/articles/s41467-023-43269-0, DOI: https://doi.org/10.1038/s41467-023-43269-0

Media contact:

Prof. Dr. Christian Kurts
Institute of Experimental Immunology
University Hospital Bonn, University of Bonn
Phone: +49 228 287-11050
Email: ckurts@uni-bonn.de

Prof. Dr. Jan-Eric Turner
Center for Internal Medicine
University Medical Center Hamburg-Eppendorf
Phone: +49 40 7410-54167
Email: j.turner@uke.de

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview